{
  "asset": "TALVEY (talquetamab)",
  "query_terms": [
    "TALVEY (talquetamab)",
    "talquetamab",
    "TALVEY"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT06285318",
      "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "lead_sponsor": "Janssen-Cilag Ltd.",
      "collaborators": [],
      "interventions": [
        "Teclistamab",
        "Talquetamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
    },
    {
      "nct_id": "NCT06208150",
      "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Pomalidomide",
        "Teclistamab",
        "Elotuzumab",
        "Dexamethasone",
        "Bortezomib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
    },
    {
      "nct_id": "NCT03399799",
      "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Hematological Malignancies"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03399799"
    },
    {
      "nct_id": "NCT05757973",
      "title": "Pre-Approval Access Named Patient Program for Talquetamab (JNJ-64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "phase": null,
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab"
      ],
      "last_update": "2025-12-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05757973"
    },
    {
      "nct_id": "NCT06577025",
      "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel",
        "Talquetamab",
        "Daratumumab",
        "Teclistamab",
        "Bortezomib",
        "Lenalidomide",
        "Dexamethasone",
        "Cyclophosphamide",
        "Fludarabine"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
    },
    {
      "nct_id": "NCT06500884",
      "title": "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Relapse Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Prophylaxis A",
        "Prophylaxis B",
        "Prophylaxis C"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06500884"
    },
    {
      "nct_id": "NCT04108195",
      "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Talquetamab",
        "Teclistamab",
        "Pomalidomide"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
    },
    {
      "nct_id": "NCT05503550",
      "title": "Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "phase": null,
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab"
      ],
      "last_update": "2025-12-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05503550"
    },
    {
      "nct_id": "NCT05695508",
      "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "University of Heidelberg Medical Center",
      "collaborators": [
        "Janssen Research & Development, LLC",
        "Deutsche Studiengruppe Multiples Myelom (DSMM)"
      ],
      "interventions": [
        "Teclistamab (Tec)",
        "Daratumumab",
        "Dexamethasone",
        "Lenalidomide",
        "Bortezomib",
        "Talquetamab",
        "JNJ-79635322"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05695508"
    },
    {
      "nct_id": "NCT05972135",
      "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "SCRI Development Innovations, LLC",
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "Teclistamab",
        "Talquetamab",
        "Tocilizumab"
      ],
      "last_update": "2025-10-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
    }
  ]
}